Yahoo Finance

enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data ...

enGene reported a promising efficacy signal for detalimogene in LEGEND cohort 1 with a 62% six‑month complete response, ...